Solventum Corporation

Good afternoon, my name is Audra and I will be your conference call operator today. I would like to welcome everyone to Solventum's fourth quarter 2025 earnings call. As a reminder, this conference is being recorded. All lines have been placed on mute to prevent any background noise. I would now like to turn the program over to your host for today's conference, Amy Wakeham, Senior Vice President of Investor Relations and Finance Communications. Please proceed.

Thank you. Good afternoon and welcome to Solventum's fourth quarter fiscal year 2025 earnings call. Joining me on today's call are Chief Executive Officer Ryan Hansen and Chief Financial Officer Wade McMillan. A replay of today's earnings call will be available later today on the investor relations section of our corporate website. The earnings press release and presentation are both available there now. During today's call, Our discussion and any comments we make will be on a non-GAAP basis unless they are specifically called out as GAAP. The non-GAAP information discussed is not intended to be considered in isolation or as a substitute for the reported GAAP financial information. You're encouraged to review the supporting schedules in today's earnings press release to reconcile the non-GAAP measures with the GAAP reported numbers. Additionally, our discussion on today's call will include forward-looking statements, including, but not limited to, expectations about our future financial and operating performance. These statements are made based on reasonable assumptions. However, our actual results could differ. Please review our SEC filings for a complete discussion of the risk factors that could cause our actual results to differ from any forward-looking statements made today. Following our prepared remarks, we'll hold a Q&A session. For this portion of today's call, please limit yourself to one question and one related follow-up. If you have additional questions, you're more than welcome to rejoin the queue. I'd like to now hand the call over to Brian.

All right. Thanks, Amy, and to all of our shareholders and everyone else that's interested in the Solventum story. I just want to say thanks for joining us today as we review our fourth quarter and our full year results, along with our 2026 guidance. We closed 2025 with solid momentum, making significant progress in our first full year as a standalone public company. Looking back at the year, I'm very proud of what we accomplished. We formally launched our long-range plans. and prioritize five growth drivers that are expected to now deliver more than 80% of our future growth. We built an experienced leadership team with strong MedTech experience, but also strong transformation experience, solidified our mission and culture, revamped our innovation process, restructured our global sales organization, and through our SKU rationalization program, sale of our purification and filtration business, In acquisition of Acera, we rapidly advanced our portfolio strategy as well, all while managing the separation process from 3M. And inside of that, throughout the year, we consistently delivered on our strategic, operational, and financial commitments. We improved volume growth, outperformed expectations, and tripled our annual sales growth from a year ago. I think it's clear that we are moving toward our long-range revenue targets faster than expected. and have programs in place to overcome external headwinds and execute against our margin targets as well. This team's capacity to deliver results while navigating ongoing separation efforts, ERP implementations, and acquisitions and divestitures is a testament to the strong talent and culture we've already built. And building on the foundation of our Salesforce restructuring project, our revitalized innovation process has meaningfully increased our vitality index, and as a result, We now expect a solid cadence of new product launches in our growth driver areas to drive further momentum with this more optimized sales team. And as our separation progresses, we are gaining full ownership of our IT systems and freeing up needed resources to drive greater overall savings and efficiencies. Our Transform for the Future program was built to capture this opportunity, and its impact is reflected in our 2026 operating margin outlook. Okay, moving to our quarter results. Well, the fourth quarter reflects another quarter of progress and provides a solid foundation as we head into the new year. And during the quarter, we announced and closed our first tuck-in acquisition, Acera Surgical, which not only opens the door to the fast-growth synthetic tissue market, it also very well complements our existing technology categories and our call points. And as we move forward, portfolio optimization will remain a key lever for value creation here at Solventum. In other words, we will continue evaluating attractive assets to acquire and assessing our current assets for go-forward fit. And our business performance and resulting healthy balance sheet now provide flexibility to return capital to shareholders. And during the quarter, we announced a $1 billion share repurchase program, which we began executing in January of this year. We see this. as a clear and important step in achieving a more balanced capital plan. Okay, moving to our business performance in the quarter. Overall, we delivered solid sales growth with dental solutions and MedSurg performing better than expected. Starting with MedSurg, we continue to leverage our existing brands, our new product innovation, and newly specialized sales teams, and are seeing traction in each of our growth driver areas, which, as you probably remember, are negative pressure wound therapy, IV site management, and sterilization assurance. In our advanced wound care business, we saw continued growth in negative pressure wound therapy, supported specifically by double-digit growth in Provena and ongoing expansion of our innovative back peel-in-place dressing. As mentioned earlier, we recently closed the Acera acquisition, which will now be a part of our advanced wound care business. We're obviously very early in the integration process, but sales teams across our newly combined business will now have access to an expanded suite of technologies to offer our joint customers. And with our combined clinical differentiation, our robust DME and differentiated infrastructure, and proprietary technology, we have a meaningful runway for growth acceleration in this business. In the infection prevention and surgical solutions business, we saw better than expected growth supported by our two growth driver areas, sterilization assurance and IV site management. Inside sterilization assurance, our strong brand equity continues to provide a solid foundation for our dedicated sales force, and early momentum from our three attest sterilization product launches will continue to support the team's momentum to drive growth going forward. In IV site management, demand for Tegaderm CHG remains strong, and our global launch continues to gain momentum. We have meaningful clinical differentiation, and our specialized sales teams are focused on converting customers from standard films to this high-value solution that reduces the risk of infection. Tegaderm CHG is still significantly underpenetrated, providing a clear runway for continued growth. And in our dental solutions business, our core restoratives growth driver was again a key component of our performance in the quarter and was supported by our strong existing brands, recent new product launches, and the Salesforce specialization that we put into place in 2025. From a new product launch perspective, we continue to see strong demand for products like ClinPro Clear and Filtech Easy Match, and overall new product sales are driving the majority of our underlying business growth. In building on last quarter's service improvements, the dental team once again significantly reduced back orders, which also contributed to growth in the quarter. Our health information systems business delivered another solid quarter, supported by its growth driver, revenue cycle management. And we continue to see adoption of 360 encompass progress against our international expansion efforts and gains in autonomous coding. And relative to autonomous coding, our strong automation and acceptance rates are further positioning us as the largest and, importantly, most capable autonomous coding vendor. Over decades, we built deep rules and algorithms designed to ensure accurate and compliant reimbursement coding. This, combined with our vast datasets and proprietary workflows, uniquely positions us to leverage AI-driven autonomous coding our customers can trust. And in summary, we finished the year building on the success and the momentum we achieved in the first three quarters. And it's clear to me that we have the right team and strategy and our momentum will continue into 2026 and beyond. And with that, I want to thank our global team for their hard work and ongoing commitment to our mission. It's you that are making a difference every single day by delivering for our patients, our customers, and our shareholders. And with that, I'll turn the call over to Wade to review our financial results and our 2026 guides. Wade, I'll just pass it to you.

Thanks, Brian. We reported another solid quarter as we completed our first full year as an independent public company. We made progress across both our transformation phases and turning around the business. Our commercial improvements yielded a significant increase in our organic sales growth, putting us on an accelerated path to reach our long-range plan sales growth targets. During the year, we were able to absorb tariff headwinds and expand operating margins off of the Q4 2024 baseline while continuing to invest in commercial enhancements and innovation. We also moved quickly on portfolio optimization, resulting in accelerated execution of our capital plan to pay down debt. Our progress to date, combined with our planned strategies, positions us well to deliver our long-range plan margin and free cash flow targets. I'll start with an update on our separation activities, status of portfolio moves, and then transition to our quarterly and full-year financial performance, concluding with the discussion of our 2026 full-year guidance. Overall, our work to complete the separation from 3M is going very well thanks to the dedicated separation management teams at both 3M and at Solventum. We are progressing well on major milestones as we have now exited over 40% of our transition service agreements from 3M and remain on track to exit approximately 90% by the end of 2026. ERP deployments continue to roll out with a plan to be complete this year. We've just gone live with our latest ERP deployment earlier this month across Asia Pacific, including China and additional countries in Europe. We have also transitioned approximately half of the more than 1,000 systems to gain system independence from 3M, which is a significant step in our separation. Regarding supply chain, we've taken further steps to separate from 3M and have now reduced our distribution center network to 55 locations, progressing towards our goal of 45. The P&F divestiture activity continues to progress as planned with a target completion at the end of 2027. There is close collaboration to ensure business continuity from Solventum to support the buyer's integration efforts across the nearly 200 transition service agreements. Shifting to our recent Acera acquisition, our early integration efforts are off to a good start following the close at the end of December. Our main focus is sustaining and accelerating the momentum that the team has generated in recent years. Now, turning to our Q4 results. Starting with top line performance, sales of $2 billion increased 3.5% on an organic basis compared to prior year and declined 3.7% on a reported basis, which reflects the first full quarter impact of the P&F divestiture following the sale in September 2025. Foreign exchange was a 170 basis point benefit to reported growth. While the net impact of the PNF divestiture and Acera acquisition represented an 890 basis point net impact on our reported growth. Overall, we have stronger than expected sales growth driven by med-surg and dental. Volume remains the main driver of growth and pricing remains within the expected range of plus or minus 1%. Our FKU rationalization program also remains on track, with 70 basis point impact in the quarter, bringing the full year impact to 60 basis points. Moving to the segments, MedSurg delivered $1.2 billion in sales, an increase of 3.2% on an organic basis. Within MedSurg, the advanced wound care business grew 1.7%. Solid performance in our negative pressure wound therapy growth driver was partially offset by headwinds in the separate advanced wound dressings category, which was impacted by SKU exits and back orders. Infection prevention and surgical solutions continues to outpace our expectations, delivering 4.2% growth that was driven by strong business performance partially offset by the remaining reversal of first half volume timing and the SKU rationalization program. Our dental solution segment delivered higher than expected 343 million in sales, an increase of 5.9% on an organic basis. Growth was driven by core restoratives, which benefited from further backorder improvement. During 2025, the supply chain team led multiple efforts that helped reduce backorders to historic lows. On a normalized basis, dental grew closer to 3%. Our HIS segment also contributed to our performance with 348 million in sales, an increase of 3.2% on an organic basis, driven by revenue cycle management software solutions and performance management solutions. Together, this growth more than offset expected declines in clinician productivity solutions. Looking down the P&L, gross margins were 53.5% of sales, a 230 basis points sequential reduction, which reflects higher logistics costs and timing of manufacturing performance. Higher logistics costs were mainly driven by ERP and distribution center cutover mitigation efforts in the quarter. These headwinds were partially offset by the benefit of the P&F divestiture. On a normalized basis, gross margins were closer to 55%. Sequentially, operating expenses reduced to $672 million from $739 million, which reflects the P&F divestiture, timing of project spend, and cost management. We delivered adjusted operating income of 397 million, or an operating margin of 19.9%, below expectations due to gross margin headwinds, partially offset with lower operating expenses. Moving down the P&L to non-operating items, our net interest expense and other non-operating spend improved versus Q3, driven by a 30 million reduction in interest expense and higher interest income. These improvements are due to the full quarter benefit of the P and F divestiture, which resulted in a 2.7 billion debt pay down and a higher cash balance. Lastly, our effective tax rate of 16.6% was favorable due to an end of year release of tax reserves and a regional tax provision in combination with favorable geographic mix. We delivered earnings per share of $1.57 driven by sales outperformance as headwinds and gross margin were partially offset with operating expense savings. Shifting to our balance sheet, we ended the quarter with just under $900 million in cash and equivalents and net debt of $4.2 billion. This includes funding the $725 million Acera acquisition, which closed on December 23rd. We're in a healthy position to accelerate our capital allocation strategy as indicated by our recent $1 billion share repurchase authorization and maintain flexibility to pursue tuck-in M&A. We generated cash flow of $33 million below our expectations due to higher divestiture costs, the earlier than expected close of the Acera acquisition, as well as higher costs to support the ERP and distribution center cutovers. Now, moving to full year 2025, we delivered 3.3% organic sales growth ahead of our expectations of 2 to 3%. When normalizing for SKU exit impact and mainly the benefit of backorder improvement in dental, our growth was approximately Operating margins finished at 20.5%. Within our assumptions of 20 to 21%. While absorbing 65 basis points of tariff impacts. That were not contemplated at the beginning of the year. We also completed the solvent and way restructuring program. exceeding expectations and delivering annualized savings of approximately 125 million at a lower total cost of 90 million. Our adjusted tax rate of 19.1% was also better than our assumption of 20 to 21%. At the bottom line, we generated non-GAAP earnings per share of $6.11, also ahead of our expectations of $5.98 to $6.08. Free cash flow was negative 10 million below our expectations of 150 to 250 million due to higher Q4 costs to support portfolio moves and ERP cutovers. Excluding these, we were in line with our expectations. When adjusting for the P&F divestiture and separation costs during 2025, pre-cash flow would have been approximately $1 billion for the year. Now, turning to our 2026 guidance. Starting with our top line, we are guiding to an organic sales growth range of 2 to 3 percent. This translates to 3 to 4 percent excluding the continued estimate of 100 basis point impact of FKU exits for 26. While not reflected in our organic sales growth outlook for 2026, we expect our recent ACERA acquisition to contribute meaningfully to our reported growth going forward and will roll up as part of advanced wound care sales. We also expect a modest 100 basis point tailwind for foreign exchange, mostly in the first half. Looking down the P&L, we estimate operating margins of 21% to 21.5% for the year, expanding from the 20.5% full year 2025. Underlying the 50 to 100 basis points of margin expansion is a combination of sales leverage programmatic savings for supply chain, and our Transform for the Future program. We expect portfolio optimization for divestiture and acquisition activity to be neutral to operating margins. Regarding tariffs in place before last week's Supreme Court ruling, we estimate full year impact of 100 to 120 million. Given the evolving nature of the environment at this time, we are assuming the impact under any new tariffs will be within a similar range. For earnings per share, we are guiding to a range of $6.40 to $6.60. For free cash flow, we are expecting approximately $200 million in 2026, excluding mainly the impact of costs that separate from 3M, as well as payments due to 3M and costs that support the recent divestiture, we would expect to be closer to $1 billion. As a reminder, separation costs reduced significantly in 2027 as we complete the separation from 3M. Other considerations for 2026 include capital expenditures of $400 to $450 million, an effective tax rate between 19.5 percent to 20.5 percent, and non-operating expenses of $300 million. primarily due to net interest expense of around $270 million. To provide some additional color related to our first quarter of 2026, remember we had a tough comparison given the approximately 180 basis points of additional sales volume benefit in the prior year. And on gross margins, Q1 will reflect the typical sequential seasonal pressure while year-over-year will reflect the additional tariff impact headwinds. All in, we anticipate operating margins will again be the lowest of the year. In conclusion, we delivered another strong quarter to complete our first full year post-separation. We're making great progress on our separation from 3M and on our portfolio moves to divest P&F and integrate ACERA. And we're moving with urgency towards our long-range plan goals of accelerating sales growth to 4 to 5%, operating margins of 23 to 25%, growing earnings per share at a 10% CAGR, and free cash flow conversion rate above 80%. We want to extend our gratitude to all Solventum team members for their hard work and commitment to our values and mission, enabling better, smarter, safer healthcare to improve lives. while consistently delivering or exceeding on our financial goals. With that, we'll hand it back to the operator for the Q&A portion of the call.

Thank you. We will now begin the question and answer session. If you would like to ask a question, press star, then the number one on your telephone keypad. If you would like to remove yourself from the queue, press star one again. As a reminder, please limit yourself to one question and one follow-up. We'll take our first question from Travis Steed at Bank of America.

Hey, thanks for taking the question. I guess first on margins, Wade, I don't know if there's anything one time in Q4 that it was a little light versus the street and the quarter. And then on 2026, you can maybe elaborate a bit more on kind of what's assumed in that 50 to 100 basis points. How much of the $500 million cost savings is baked in into that and anything else that you'd kind of frame up for the margins in 2026?

Sure I Travis so margins obviously important part of our story, as we think about Q4 first approximately 150 basis points of the cost in our gross margins. was one time in nature. So you'll see in our prepared remarks that we shared a more normalized gross margin of 55% is more what we would have expected. And we saw a lot of separation activity in Q4, so it ended up just costing us more. If we think about operating margins, certainly lower than we expected, but really just driven by that headwind in gross margins, we were able to offset it partially with some savings in our operating expenses, And then as we think about 2026, first of all, I'll just say we are committed to growing our sales as well as expanding operating margins each year. And so in that theme, we're now planning to expand operating margins 50 to 100 basis points in 2026, as you mentioned. A couple of things that are important here, certainly tariffs are a headwind for us again in 2026. People may recall that we have a very fast inventory turn. And so we had approximately two quarters of impact tariffs in 2025. And so we'll annualize that in 2026. You'll see from our prepared remarks, it's about a doubling of the tariff headwinds for us. And so with that in mind, it's a pretty significant margin expansion. The drivers of that are sales leverage as we continue to drive sales on an accelerated basis. as well as our programs within gross margin. We've talked about programmatic savings. We gave a lot of detail at our investor day, and we've got significant effort to drive favorable gross margins over time. And then, as you mentioned, Travis, our more recently announced transform for the future restructuring project which is a longer range project that is targeting several areas of efficiency and we will start to see some of that in 2026 but it'll benefit us more over the long term so we put all that together we do think we've got a nice operating margin expansion story again in 26 despite the tariff estimate that we have in the numbers at this time okay thank you and i guess uh my follow-up question since there's been more focus on the healthcare i.t business and

and some of the AI stuff that's going on, just would kind of love to give you the opportunity to kind of maybe explain that, uh, and explain your business a bit more for investors.

Yeah, thanks, Trevor. I'll probably answer that one. And I assume seeing your note that you might ask that question. So, um, We were actually betting which question you would ask first, and you asked both questions. You know me well. I know you pretty well. So I would just say, first of all, I think it's important to state right out of the gate, we actually see AI as an opportunity more than we do a threat. I think that's, you could probably end the statement there, but I think that's a really important statement to make. And then there's probably three vectors to look at it, which I think could be helpful to people. Number one, I think we see artificial intelligence as a lever to drive autonomous coding. That's why we've been spending so much in that area. And that's what's driving us in autonomous coding. But we don't see it by itself as the answer to autonomous coding. I think that's important. By itself is not the answer. It's just a piece of the equation. And we really don't see AI, again, by itself as a competitor. We see it as a tool. to solve for autonomous coding. Remember, autonomous reimbursement coding, not computer coding, right? And then three, and this is important because AI will be available to anybody who wants to use it in autonomous coding or revenue cycle management. We truly do believe that we're differentially capable of using AI because number one, we've been in the market for decades. And as a result of that, we have vast, a number of proprietary, I'm going to call algorithms and rules that we have around reimbursement coding, actually close to a million plus of those rules and algorithms, which is substantial. And of course, because we've been working at scale with hospitals, we have very vast data sets as well. So we really believe that what we have available to us allows us to train AI in ways that others can't. So we actually look at this as an opportunity more than we do a threat. But I appreciate you asking the question because there's a lot of folks that may not see it that way. Great thanks a lot. Yeah no problem thanks Travis.

We'll move next to Jason Bednar at Piper Sandler.

Hey afternoon everyone thanks for taking the questions. Wade I wanted to come back to some of the guidance points you were making. I appreciate all the color around the first quarter. Maybe wanted to give you an opportunity to talk if there's any other sequential call outs. Last year 25 was was lumpy. It was good lumpy, but lumpy in that you had the ERP cutovers, the DC cutovers that, you know, just created some volatility in the volume. So anything else you'd call out as we try to model throughout the year? And then, you know, within that also in the first quarter, should we be considering any headwinds tied to just some of the weather dynamics that, you know, may or may not have impacted volumes for your businesses in the first quarter here?

Got it. Hi Jason. Yeah, I can certainly start that one for you and I'm glad you picked up on the key one comments that we had in our prepared remarks because it is the one quarter for us. It's a little more challenging that the other quarters in the year look more stable, so maybe I'll just summarize the information that we shared and it's really in the three areas. Sales, gross margin and OPEX. So for sales we had 180 basis points of tough comp and that's. put a lot of pressure on our Q1 sales here. And so if you just take the full year guide of 2% to 3%, and you take the midpoint 2.5, if you use the 180 basis points of headwind, you get just under 1%. And so that's how we'd like people to think about the first quarter. And I think that'd be a reasonable place to start. If you move down the P&L operating margin, is setting up to be the lowest of the year in q1 sequentially down from q425 to q126 but that's similar to what we experienced last year in 2025. so very similar setup to last year and that's really driven by gross margins which relative to the normalized 55 we gave for q4 we would expect to see some normal, sequential, seasonal headwind to that moving from Q4-25 to Q1-26. So same setup again as last year. Keep in mind, tariffs are a headwind in the first half as well before we annualize them. And then when you move down to operating expenses, kind of similar here, we'll have higher OpEx in Q1 as we have some seasonally higher expenses than Q4-25. And Q4-25 was a little unnaturally low as we had some favorable project timing. And then just given the gross margin pressures we were having in the quarter, we did some cost reduction initiatives that gave some favorable op-ex in Q4 as well. We don't have any weather specific things to that specific question, Jason, nothing that we would call out. And then again, I would just say for the remainder of the year, the setup looks more consistent, other than I would just highlight, and it was really the driver of that volume in Q1, this first half, second half impact of IPSS. We had a lot of volume mainly in the first half last year. mostly ERP timing-driven impacts. But the good news is they're all contained within the year. So first half, second half dynamic, mostly a Q1 additional volume, Q3 giveback. But the good news, the story actually gets quite simple at a full year basis, but there is that tradeoff, particularly in the IPSS, between mainly Q1 and Q3.

All right. Super helpful. Thank you for that. um brian i wanted to shift over to you um bigger picture question you mentioned product pipeline that's expanded um you know within some of the core growth categories you've identified or you identified at your investor day um can you give us a sense as to some of the things you're more excited about or expected to be more impactful when we look out this year and also next year really to help bridge to that four to five percent growth target Knowing that you're targeting 3% to 4% underlying growth this year, what helps accelerate you that last 100 basis points to get to those LRP targets you have out there?

Yeah, yeah, appreciate the question. And I would say, you know, maybe first just taking a step back because I have a feeling some of our solvers are listening to this call as well. And I just want to say that I appreciate the work that they put into revamping and revitalizing our innovation process. And it's paid dividends, you know, as we talked about in the prepared remarks. Vitality index has gone up and the cadence is more focused to products that we're going to see. I'm not going to speak specifically about any individual product because, you know, competitive reasons, but maybe I'll give you some color that I think could at least help. We've got close to 20 new products that we're going to be launching now over the next two years, relatively evenly over those two years, so it's not back-end loaded. And those, as you would expect, just given the size of mid-surge, almost half of those are going to be in mid-surge. The other half is split between HIS and dental. And as you would expect, a decent portion of those are going to be inside of the growth driver areas. But it's not just those. I kind of look at it as a three-legged stool, right? You've got this opportunity for new products. in that revitalization of innovation that I've been talking about. But we also have existing products and brands that are really strong in the marketplace. And I think some people underappreciate the fact that they're also underpenetrate. So with the new specialized sales organization, we can get after that underpenetration, even with existing brands. And the third leg of the stool is just the commercial enhancements we've made. And those really have three components to it. First is specialization, which is probably the most important. But we're also training those individuals now to be more clinically adept, which is very important when you have clinically differentiated technology. And the final one is just to make sure that we have a sales operations team that is best in class to focus the organization and to make sure that they have the tools to be successful in the field. So it's all three of those really that's driving the growth.

All right. Thank you. Yeah. Thank you.

We'll go next to Kevin Caliendo at UBS.

Thanks for the question. This is Dylan for Kevin. Maybe for a minute, could you guys talk about the strong outperformance in dental this quarter? Again, you grew organically nearly 6%. How much of that was volume expansion versus price capture related to or not related to tariffs? And what do you think a normalized growth rate looks like in dental? you know, controlling for any sellouts or unusual comps.

Okay. Yes. So, again, that was another one we thought we'd probably get a question on because it was a pretty standout quarter, again, for dental. So, again, because I know they're listening to the call, congratulations, great quarter. And I would say that probably the – well, I know. The biggest underlying reason for growth is new products. They have done a nice job. of revitalizing innovation, launching new products, and that's really what's driving our underlying business performance. Now, in the quarter, I think we said in the prepared remarks that another factor was backorder recovery. That's the second quarter in a row they've done a really good job of capturing backorder recovery, and that's boosting us. That's more of a one-time thing. I wouldn't think about that as a go-forward opportunity, but it definitely helped us in the quarter. When we think about the market, because I know that's probably inside of your question as well, because I'm sure you're covering other companies in dental, we kind of look at it the same as what you're hearing from others. It's a stable to maybe slightly improving market, but that's really the way we look at it. Stable market, slightly improving. We would expect that to go forward in 2026, but really the momentum here is the new product development. They're just doing a great job with that specialized sales organization driving it right now.

Appreciate it. Thanks for the question. Yeah, thank you.

Did you have another one? I didn't want to cut you off there. Sorry about that.

Oh, sorry. Yeah, if I had a moment. Looking at the $500 million, the Transform for the Future program, and apologies if this was hit on earlier, but, you know, what should we contemplate regarding the phasing of those, both the costs going into the restructuring and the timing of the benefits?

um you know is that really a big growth driver um discreetly as we look at the benefit for 26 or is the phasing more you know 27 and thereafter that's the way brian can start that one if you want so obviously a very important program for us it is a multi-year program from starting this year 2026 into 29 and 30. Maybe just to highlight, you know, as you said, it's a $500 million cost takeout program. It's meant to support both margin expansion as well as opportunities to meaningfully invest for growth. We want to make sure that we're driving efficiencies that despite things like tariffs, we've got enough efficiencies going so we can continue to reinvest for growth given the importance of us continuing to drive and accelerate that sales growth line. Maybe it's a little bit more about the program itself. It's targeted at transforming our cost structure. I mentioned the operational efficiencies and then repositioning us for that profitable growth. We'll be looking at streamlining systems, increasing automation. It's a really comprehensive program. To your question on the phasing, we haven't given details on that. We're still developing the program. As I said, it's a multi-year program. But I would say just generally, we will start to benefit from the program in 26, but the majority of the benefits will be in 2027 and beyond, as it just takes time to put the programs together and then execute on them.

One other thing maybe to add to that too, it's very important about this program, it is a cultural shift. for our organization all around the concept of continuous improvement. We've got this mantra here that we can be satisfied, we can be happy, but we can never be satisfied, right? So we can be happy and celebrate success, but we can always get better. And that's what this program is. It really is the concept of transforming for the future through continuous improvement. And it's not just at the senior level of the organization. This transcends the organization. We're asking everybody to get involved in the program. So it really is a cultural event, not just a savings program.

you and appreciate the questions yeah of course we'll take our next question from ryan zimmerman at btig uh good afternoon thanks for uh taking our questions um you know just following up on the his comments and and you know there's been a lot of investor focus on this uh late i i appreciate your answers earlier brian i i got to dig a little deeper though and just kind of ask know is there any guardrails that you know you want to put around this you know if if this is up for competitive you know bidding or competitive entrance and so forth i mean how should we think about maybe what's contractually obligated you know over a certain time period or any other additional details i think you can give that you know again kind of you know isolates what impact there may or may not be around the his business

Yes, so I would tell you two things here. Number one, we have pretty long contracts, multiple-year contracts, and so we feel comfortable. And I don't want to rest on that because I do believe we have significant differentiation here. We're a leader today. We absolutely expect to be a leader in this transformation in the future. There's no question in our minds. But we do have contractual obligations in our favor, and there's switching costs associated with this. It doesn't happen overnight. And I think very importantly for people to remember here is you make mistakes, even small ones, in your reimbursement model, in your coding. Not only do you lose revenue, you have the risk of compliance concerns. And there's a trust factor that goes into that. As a matter of fact, we look at autonomous coding competitors as risking autonomous coding because we don't think they're going to do it the way we would do it, right? Again, using all those rules and all those algorithms that we have that are proprietary to us. So we truly do believe we're going to win. going to transform we're already leading we feel like we're going to continue to lead uh and and we do believe we really do believe that uh that that's just the way it's going to be i i don't see this at this point in time as a risk i see it as an opportunity and the contractual piece helps but we're not going to rest on that yeah no that's that's helpful i appreciate the color there and then you know maybe turn into a sarah um

What are you embedding for expectations on Acera if you can provide any high-level commentary around it? I mean, I think it was doing, call it $90 million at the time of acquisition. And so where can that sustain once it turns organic and from a contribution and growth standpoint?

Well, I'll tell you, we wouldn't have bought the asset if we didn't believe that it had a real opportunity to help advanced wound care, med-surg, and the total business from a revenue growth standpoint. So we feel like it's a great starting point, but it is just a starting point. And to give you some perspective on it, they're in a billion-dollar market growing 10% right now, and they're in a subcategory of synthetics inside of that market that's more attractive, and they've got differentiation in that space. So it is a healthy double-digit grower for us. And I want to continue to remind people, it's in the space we already play and have commercial infrastructure. So we have a force multiplier effect, even our two organizations coming together from a commercial standpoint, but also eventually from an innovation perspective. So I feel really good about this as a separate growth avenue for advanced wound care for the total business. And it's profitable. It's really nice profitability.

Thank you.

Thanks, Brent.

We'll move next to David Roman at Goldman Sachs.

Thank you. Good afternoon, everyone. Maybe I could just go into the dental dynamic in a little bit more detail here. And I think last quarter, there were some more set of dynamics at play here. But maybe, Brian, if you kind of maybe template dental as one of the businesses where you have new, I think you said in the follow-up last quarter that it is a good example of when you have new products, what can happen to the top line, but you're seeing David Casimir- kind of that impact in one of those slower growing categories that you serve so so maybe you could just extrapolate the experience and dental to when we could when you think it's reasonable to expect that same dynamic to play through in. David Casimir- med surge and NHS and it just had a follow up on on the buyback.

Yeah, David, thanks for the question. And I agree. I think dental laid out the roadmap that was pretty clear to people, but you're already seeing it in MedSurge. It's not just the commercial enhancements that we made. We are launching new products in both MedSurge and HIS. Just to recap, I'll give you some of them, not a full list of them, but Backfeeling Place was a big one. Tegaderm CHG was launched in the U.S., but now it's on a global launch. So we're rolling that out around the world. We've had CHG and Ioban as well, which is a new product that we use in surgical procedures. We've had three attest sterilization products. The EBOE DIC was also launched. So we've had a number of products launched in MedSurge. And in HIS, you've seen various applications in autonomous coding and a lot of applications for Encompass 360 when we look at outside the U.S. implementation. So they're not... not having product launches right now. The key thing that's driving those product launches is the commercial enhancement. We didn't have those before. And as a result, those products are being launched into a void, if you will, a general sales organization. So we're already beginning to see the momentum from those new products. And as I said before, we've got almost 20 new products coming over the next two years.

Got it. And then maybe, Wade, it looks like the share count still stepped up on both the year-over-year and sequential basis. You obviously announced the large buyback authorization in November. How are you thinking about deploying the buyback? I think that there was quite a bit of volatility in the stock over the past several months. So maybe what... What's sort of the strategy behind the buyback and what are the factors that would drive you to deploy it either on a programmatic or more significant basis?

Sure. Hey, David. So I think directionally it's reasonable to think about the authorization as offsetting the impact of our stock-based comp dilution and holding that share count relatively flat. I think that's one of the objectives that we have. As you said, without a share repurchase in place over the previous year, our share count went up. And so one of the major goals here is to number one, offset that stock based comp. And then over time, you know, it is an opportunity for us. We've got room within the authorization framework. If we see a need or a reason, depending on performance of the share price, to potentially purchase more shares. Obviously, if we do something like that, we have to work it through with our board and make those decisions as well. But I think just taking a step back, we're very happy with the accelerated capital plan over the last year with our ability to pay down debt. And if you remember back from our investor day, that was the primary objective. Most spins spin with a pretty significant amount of debt, and one of our primary goals was to pay down that debt. We did that in accelerated fashion, and now we're in a position to have more balanced return and returning capital to shareholders via this authorization. So as Brian said in his prepared remarks, we started that in January. This is our first quarter, and we're pretty excited to be moving in this direction as well. Great. Thanks so much.

Thanks, David. Our next question comes from Brett Fishpin at KeyBank Capital Markets.

Hey guys, thank you very much for taking the questions. First, just wanted to ask on the overall organic revenue guidance of, you know, two to 3%. And I was curious if you could just directionally provide any commentary on how you're thinking about that across the different segments, whether we should expect any, you know, material departure from what we've seen on a normalized basis in 2025. And then also if the 100 basis point impact from SKUs would be more pronounced in any specific quarter.

Brian, I'm going to start that one.

Maybe to rephrase that question on any specific quarter, you could maybe answer that, but also any specific business.

Yeah, that's the key. So, yeah, maybe we'll start there. We don't see a significant difference across the quarters from the program. at this time and so nothing to share there. But as Brian just highlighted, we do see a significant more impact within MedSurg and particularly the IPSS business. So as we move from 60 basis points of impact in 25 to 100 basis points of impact in 2026, we'll see the majority of that 100 basis points hitting in the IPSS and MedSurg business And then back to the front end of your discussion, and Brian can start that one. We obviously put a lot of thought into this guidance, and I'm glad you brought it up because it gives us an opportunity to talk a little bit about it. We did intentionally share that for 2025, our sales growth rate on a normalized basis was about 3.5%. And that's important stake in the ground for us. It's really normalized for both the SKU program as well as mainly the dental back order. And so, with that 3.5% in mind, the way we looked about our guide for 2026 is we put that at the midpoint of our X skew guide. You know, we're 2% to 3% guide for 2026. On a 100 basis point skews, we're guiding 3% to 4%. So, what that really means is if we continue to perform at an accelerated rate here in 2026, we had – Greg Aaronson, Big step up in our growth in 2025 and if we continue that momentum continue to perform at that level, be at the midpoint of our guidance for 2026 and, of course, at the high end. Greg Aaronson, More 4% on an execute basis will be above last year strong performance and we're very focused on getting to that because then that would put us. On an accelerated basis, getting to the low end of our 4 to 5% target for a long range plan. And so on an execute basis, the high end of our guidance is already touching the low end of our long range plan guidance for 2028. So we do feel that 2025 was a very strong year where we really accelerated the sales growth rate. We shared some of that detail in our prepared remarks, so I won't repeat it here. But that's some color in behind the full year. You did call out segments as well. As you know, we don't guide at the segment level, but it could provide a little bit of color here. Overall, we expect all segments to improve their underlying growth year over year. And again, the momentum that we see in the business, if it continues, will be at the high end. All right, great. And then, oh, sorry, go ahead.

Because it would be MedSearch is going to be impacted more by SKU, and obviously dental is going to be impacted by the backward recovery comp. But outside of that, no major impacts to the businesses.

All right, that was super helpful. And then just for my follow-up question, I wanted to ask, you know, during the fourth quarter, you announced some changes to the management structure and was hoping you could just touch on, you know, your decision to implement a chief commercial officer position. And any thoughts on how that impacts the broader strategy for Soventum? Thank you.

It's funny because that feels like old news to me already. I was looking around going, what's he talking about?

Yeah, so as you know, we brought Heather in to be the primary leader of our businesses. So she's the chief commercial officer now. And I feel very fortunate to be able to bring Heather in. She and I have a history. We worked at Govidian together. She's worked with me in the past. She's a very strong operator. So it was just serendipity that she became available at the same time that Chris was going to be exiting the organization. So very lucky to get her. But it was really just the continuation of the strategy, which would have been to combine the businesses under a leader. um chris for his own reasons couldn't do that and uh and heather was available and we were able to get her which is fantastic for us i wouldn't read anything else into it other than the fact that we've got a great operator now looking at synergies across our businesses all right thank you brian yeah of course our next question comes from vic chopra at wells fargo

Hi, it's great calling in. Thanks for taking questions. My first one is on ERP. I think you have another ERP implementation coming this year. Last year when you had the European one, there was some pull forward buying in the first half. Is that something you should consider for 2026? And I have a follow up.

Yeah, hi. So ERP's obviously We've got a lot of work going on in this area. We did share in our prepared remarks that we are planning to be done with the 3M separation ERPs in 2026. And so by definition, we've still got several ERPs to go. We've got a couple of large ones, both in the first half and the second half of this year. I did share in my prepared remarks that we've we've started another wave here in February. We've got about 16 countries involved in that wave, and that's off to a really good start. And so we will have several more waves as we go along through the year, but planning again to be done by the end of the year. Regarding volume, we're not planning anything out at this time. It really is dependent upon at what point in the quarters it falls. Sometimes if it's early in the quarter, most of the, Inventory changes have washed out within the quarter. To the extent we see them, and if we see additional volume either buying ahead or being delayed as a result of the ERPs, we'll call that out in our actuals. But very difficult to predict those, so we don't call them out.

Got it. That's helpful. And then for my follow-up, you talked about pricing being plus minus 1%. In Q4, anything we should think about as far as pricing for 26, either for the overall company or across segments? Thanks again for taking the question. Sure.

Yeah, so as we've shared before, our focus for growing the sustainability of the business is all on volume. Our new products, our commercial efforts, all focused on, I shouldn't say all, almost all on volume. We certainly have pricing capability, and we've got people looking at price. We do have several areas in the business where we have the ability to raise price, and we do. But what we've shared is we expect price to be in a more normalized range of plus or minus 1%. We saw that again in Q4, and that's where we're expecting it to be again in 2026. So we don't see price being an outside driver of the business again in 2026, more in that normalized range, and our growth will really be on sustainable volume growth.

We'll go next to Rick Wise at Stifel.

Good afternoon to you both. Bob White- Brian just maybe reflect a little bit more on your updated thinking on your m&a strategy, you know is another deal possible, what are you prioritizing it as with with making. Bob White- So much progress toward to quote way to your an accelerated path to your long term targets. Bob White- Is it more likely we're going to see additional. tuck in growth-enhancing, margin-enhancing deals sooner rather than later?

I probably won't speak to the timing, but I was pretty intentional and have been for a while. It was in our prepared remarks and every time I probably talk to you and others is it is definitely a lever we will continue to flex for value creation. Support for optimization to me, and the reason why I'm leaning on it so much is I don't want people to think because we've done so much so fast that we're finished. This will be a perpetual lever that we're going to continue to flex in the organization, which will include acquiring companies on a tuck-in basis in a serial fashion to be able to drive revenue growth and profitability. That's a requirement. It's got to be mission-centric, first and foremost. It's got to be in attractive markets with strong profitability in areas that we think we can win, and we'll continue to do that. I won't speak to the timing of that, but we do have the financial flexibility to do them. So that's probably all I'll say on that, but it clearly is a continued lever for us.

Okay. And just reflecting, sort of stepping back and reflecting on the increasing probability that, or your increasing confidence in the 28 goals on sales and margins and EPS, et cetera. Maybe just, I'd be curious to hear, Maybe, Wade, for you, it's like, is it the SKU program being done? Is the debt coming down? Is it the exit of the TSA agreements? I mean, what's the relative importance over the next 12 months in terms of observing that progress and building confidence as you approach 27, 28? Thank you.

Maybe I'll start on the revenue side, revenue growth side, and you can speak more to the margin. So I'd say, you know, proof's kind of in the pudding, right? I mean, at the end of the day, you look at our growth rates, and even though we normalize them at three and a half, as we said, as Wade just referenced, that's pretty darn good, right? Out of the gate, that's almost three times better than what we had in our base couple of years before the spin and And that's great traction that we're seeing. It's coming from the commercial enhancements that we've made. It's coming from the brands that we already have. And it's coming from those new products that we've talked about. But that is giving us confidence. It was only a short period of time ago in March of 2025 that I had people questioning whether we could ever get to the LRP targets that we were providing. I think it's pretty clear we will not only get there, but we might do it faster than expected. Hopefully we do it this year. That's the goal. So I think it's really just, All the things that we put into place are coming together, and the team is making it work, even in the face of all of the challenges we continue to throw at them. Acquisitions, divestitures, ERP cutovers, separations, you name it. This team is state-focused and delivered. And again, I'll compliment the team that I know is listening. Congratulations for that. On the margin side, we've had a lot of headwinds come our way as well since we put that LRP target out. But we still feel like we've got the programs in place to deliver on those margin targets. And I think it's important, you know, when you think about us versus, you know, the organization before spin, we've got like 300 basis points of pressure that we're going to be feeling that we did not have before spin. Looking at raw material increases, looking at tariffs that we didn't have before spin. And so that 23 to 25 is really like a 26 to 28 when you look at benchmarking where we were before the spin. So I'm pretty proud of the team meeting in there as well. I probably just took everything you were going to say, Wade, so I apologize again.

No, no. I think you covered it really well, Brian. Maybe just to the sort of second part of your question, Rick, on what are the milestones or things that we need to clear along the way, you touched on a couple important ones. You know, in order to achieve those margin targets Brian mentioned, we do need to clear our separation from 3M. We are very excited. As I shared in my prepare marks, 90% of the TSAs we plan to have done here in 26. We plan to be through the ERPs here in 26. So 26 is a very important year for us, but we're pretty excited to get to 2027 and put most of that separation work behind us and move a lot of our resources, a lot of our best and brightest, focusing on the business versus on the separation process. And then maybe, Brian, I'll just clear a couple of the other metrics. We've put out earnings per share to 10% CAGR. We are very confident with the initiatives that we have in place that will be supporting that sales growth that Brian touched on, achieving those operating margins, and then driving that 10% EPS CAGR. And then the last thing is the free cash flow conversion over 80%. And we've got these transient issues that we're dealing with today around the separation costs, divestiture costs, And again, we can't wait to be complete, mostly complete with a separation in 26 and shed a lot of these additional costs starting in 27. And so once we do get beyond those, we will have very strong, we are a cash, very strong cash operating company without, again, those special projects around separation and divestiture. If you clear those out of the way, we're already at our free cash flow conversion targets. And so we're very confident And hitting all those metrics, as Brian said, sales growth with all the initiatives we have in place, operating margins with the initiatives we have there, including Transform for the Future, will lead us to that EPS 10% CAGR. And then we get beyond these transient projects and we'll be at our 80-plus percent free cash flow. So very confident on our path to hitting our long-range plan targets by 2028.

Thank you so much, Debo. Thanks, Rick.

And then next we'll move to Stephen Valicutt at Mizuho Securities.

Great. Good afternoon. Thanks for taking the question. I guess at this point it's probably more of a follow-up question, but just to come back on that topic on the TSAs and exiting 90% by the end of 26, for the 10% that's still going to be left, Just remind us again, is that really more on the supply side? And then you've talked about you have those 2027 headwinds. It was like $100 million step up in inventory cost from 3M. It might have been quantified under basis points as well. But is that the piece that would still be kind of hanging out there? Or does some of that dissipated with your progress? I just want to just connect the dots around all those components. Thanks.

Yeah, great question, Steve, and that'll help us clarify because we do get this question quite a bit. I'll just start on the 90% of TSAs is primarily around separating our systems and our ERPs as well as our distribution centers and the manufacturing that we do for 3M and that 3M does for us. And so we'll have mostly rebranding work and some supply chain work to do in 2027, that remaining 10%. But I do want to just specifically differentiate between the raw materials work that we do, and that's the additional step up that you're talking about that 3M gave themselves a contractual option to, again, step up our cost in 2027. And we've shared that that's about a 100 basis point headwind for us if that, in fact, happens again. We don't have any updates to share at this time, but we are working with 3M to see if there's a better solution for both companies, frankly, than going that route. So, you know, that'll be an update down the road. So with that in mind, we've got most of the separation work done in 2026. We do have some rebranding, some supply chain that we'll carry over into 2027. Brian, if there's anything.

I mean, maybe the only other one, because sometimes there's confusion on the raw materials piece. I just want to make sure that it's clear that with those raw materials, most of that is including intellectual property that we have access to. Actually, we own. There was concern that we didn't have that intellectual property. We have full ownership rights in our field of use. And it is transferable. We can continue to buy from 3M as a raw material supplier with that intellectual property, or we can go to another chemical manufacturer to use them as well. So I just want to be clear that even though we have that long-term supply agreement with 3M, we do have the option because we own the rights to the intellectual property to go elsewhere. Okay, got it. Thanks.

And that concludes the question and answer session. I'll now turn the call back over to Amy for closing remarks.

Awesome. Thank you, Audra, and thank you, everyone, for listening. We appreciate all your questions. If you do have any follow-ups or need to clarify anything, please don't hesitate to reach out to the investor relations team. Audra, you can go ahead and close the call. Thank you. This concludes today's conference call.

Thank you for your participation. You may now disconnect.